Reaction

Biliary Dilatation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,457 reports · 30 co-occurring drugs

As of the last recalculation, Biliary Dilatation appears in 1,457 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is LAPATINIB (PRR 18.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Lapatinib2018.718.7
Teduglutide1516.116.1
Basiliximab1113.513.5
Dalteparin Sodium912.212.2
Methadone3210.910.9
Gemcitabine Hydrochloride369.99.9
Ursosiol139.69.6
Irinotecan Hydrochloride88.98.9
Regorafenib78.78.7
Everolimus Tablets108.68.6
Pancrelipase228.38.3
Letrozole Tablets278.28.2
Sitagliptin408.18.1
Terbinafine Hydrochloride58.18.1
Sitagliptin And Metformin Hydrochloride128.08.0
Gemcitabine207.37.3
Durvalumab107.17.1
Drospirenone And Ethinyl Estradiol216.96.9
Rifaximin106.96.9
Tenofovir Disoproxil Fumarate Tablets46.66.6
Methadone Hydrochloride56.66.6
Fluticasone Furoate And Vilanterol Trifenatate166.46.4
Tolvaptan65.95.9
Fluorouracil Cream, 0.5%315.95.9
Asfotase Alfa45.75.7
Paclitaxel385.65.6
Oxaliplatin285.55.5
Atezolizumab134.84.8
Erlotinib Hydrochloride44.64.6
Abemaciclib53.63.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.